Saturday, October 16, 2021
Moderate exercise could prevent 46,000 cancer cases annually
Photo credit – Vijay.shivu via Wikipedia Creative Commons
CANCER DIGEST – Oct. 16, 2021 – More than 46,000 cancer cases annually could be prevented in the US if people could manage to get just five hours of moderate exercise per week, a new analysis shows.
|
| Photo credit – Vijay.shivu via Wikipedia Creative Commons |
CANCER DIGEST – Oct. 16, 2021 – More than 46,000 cancer cases annually could be prevented in the US if people could manage to get just five hours of moderate exercise per week, a new analysis shows.
Saturday, April 11, 2020
Immunotherapy after chemo slows bladder cancer progression
Image credit Terese Winslow via Cancer.gov
CANCER DIGEST – April 11, 2020 – Using immunotherapy immediately after chemotherapy treatment in patients with metastatic bladder cancer significantly slowed the progression of the cancer, according to results of a clinical trial led by Mount Sinai researchers published in the Journal of Clinical Oncology in April.
The trial involving 108 patients showed that the time before their type of bladder cancer called urothelial cancer progressed was 60 percent longer when they received the immunotherapy drug called pembrolizumab (Keytruda®) after platinum-based chemotherapy compared to patients who received a placebo after chemotherapy.
|
| Image credit Terese Winslow via Cancer.gov |
The trial involving 108 patients showed that the time before their type of bladder cancer called urothelial cancer progressed was 60 percent longer when they received the immunotherapy drug called pembrolizumab (Keytruda®) after platinum-based chemotherapy compared to patients who received a placebo after chemotherapy.
Saturday, February 22, 2020
Study exposes Achilles heel of deadly kidney cancer
The red dots represent the protein complex in kidney
cancer cells that spur cancer growth. The right frame
shows tumor after treatment with PT2385
CANCER DIGEST – Feb. 22, 2020 – An experimental drug already shown to be safe and helps some patients with a deadly form of kidney cancer, has shed light on a possible new way to treat the cancer.
“Short of a cure, which we’re still struggling to get to patients, we think this drug and other future drugs in this class could offer a durable way to fight this cancer while preserving quality of life,” said Kevin Courtney, M.D., Ph.D. in a press release.
 |
The red dots represent the protein complex in kidney
cancer cells that spur cancer growth. The right frame
shows tumor after treatment with PT2385
|
“Short of a cure, which we’re still struggling to get to patients, we think this drug and other future drugs in this class could offer a durable way to fight this cancer while preserving quality of life,” said Kevin Courtney, M.D., Ph.D. in a press release.
Saturday, July 14, 2018
Study Finds Robotic Surgery is as Effective as Open Surgery for Bladder Cancer
0 commentsTuesday, October 4, 2016
First new drug for bladder cancer approved
CANCER DIGEST – Oct. 4, 2016 – The FDA approval of Tecentriq ushers in the first new treatment for advanced bladder cancer in 30 years.
The drug works by blocking a protein tumor cells produce on their cell surfaces that prevents the immune system’s T cells from attacking the cancer cells. The protein tumors produce is known as an "immune checkpoint," and prevents T cells from recognizing and binding to the cancer cell, thus evading the T cell attack. This "checkpoint" protein is called PD-L1 and Tecentriq binds to it allowing T cells to land and establish a beachhead to attack the cancer cell.
The drug works by blocking a protein tumor cells produce on their cell surfaces that prevents the immune system’s T cells from attacking the cancer cells. The protein tumors produce is known as an "immune checkpoint," and prevents T cells from recognizing and binding to the cancer cell, thus evading the T cell attack. This "checkpoint" protein is called PD-L1 and Tecentriq binds to it allowing T cells to land and establish a beachhead to attack the cancer cell.
Tuesday, February 2, 2016
New advice for evaluating blood in the urine for signs of cancer
CANCER DIGEST – Feb. 2, 2016 – Physicians are being advised to take a second look at blood in the urine, or hematuria, for signs of cancer, by a new report from the American College of Physicians’ High Value Care Task Force.
The Task Force issues advice for physicians on how to detect and evaluate hematuria. The report stems from research at the University of North Carolina Lineberger Comprehensive Cancer Center.
CANCER DIGEST – Feb. 2, 2016 – Physicians are being advised to take a second look at blood in the urine, or hematuria, for signs of cancer, by a new report from the American College of Physicians’ High Value Care Task Force.
The Task Force issues advice for physicians on how to detect and evaluate hematuria. The report stems from research at the University of North Carolina Lineberger Comprehensive Cancer Center.
Wednesday, November 26, 2014
Promising drug for advanced bladder cancer given breakthrough status
 |
| Genentech video. Click to view |
CANCER DIGEST – Nov. 26, 2014 – A team of British scientists are reporting made a major breakthrough with a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years.
Led by Dr. Tom Powles, consultant medical oncologist, Barts Cancer Institute, Queen Mary University of London, the researchers published early results of a small phase I study today in the journal Nature.
Tuesday, April 1, 2014
New test may indicate bladder cancer recurrence
 |
| Non-muscle invasive bladder cancer (NMIBC) is the most common. (Fig. courtesy of Wikipedia) |
MEDICAL NEWS TODAY – Apr. 1, 2014 – A new test that measures a chemical that acts on DNA in many cell processes appears to be highly sensitive in detecting recurrence of the most common form of bladder cancer. Researchers at the University of Southern California, Norris Comprehensive Cancer Center in Los Angeles validated the test on 368 urine samples from 90 bladder cancer patients monitored over seven years. The report in the journal Clinical Cancer Research shows that the new test correctly predicted cancer recurrence 80 percent of the time, and correctly indicated no recurrence 74 percent of the time. Current methods of detecting recurrence in these patients are correct 35 percent of the time and rule out cancer accurately 15 percent of the time.
No comments:
Post a Comment